| 英文名称 |
中文名称 |
CAS号 |
操作 |
| AT9283 |
AT9283 |
896466-04-9 |
详细
|
| AST487 |
AST 487 |
630124-46-8 |
详细
|
| BIIB057 HCl |
PRT062607 (HYDROCHLORIDE) |
1370261-97-4 |
详细
|
| LY2606368 dihydrochloride |
CHK1抑制剂 |
1234015-54-3 |
详细
|
| RS-1 |
4-溴-N-(4-溴苯基)-3-[[(苯基甲基)氨基]磺酰基]苯甲酰胺 |
312756-74-4 |
详细
|
| Volitinib |
沃利替尼 |
1313725-88-0 |
详细
|
| GSK-3326595 |
GSK-3326595 |
1616392-22-3 |
详细
|
| M-2951 (Evobrutinib) |
埃沃布鲁替尼 |
1415823-73-2 |
详细
|
| leniolisib(CDZ 173) |
LENIOLISIB |
1354690-24-6 |
详细
|
| IITZ-01 |
IITZ-01 |
1807988-47-1 |
详细
|
| IWP-O1 |
IWP-O1 |
2074607-48-8 |
详细
|
| Lipofermata |
5-溴-5'-苯基-3'H-螺环[吲哚啉-3,2'-[1,3,4]噻二唑]-2-酮 |
297180-15-5 |
详细
|
| Isoxazole 9 (ISX-9) |
ISX 9 |
832115-62-5 |
详细
|
| R1487 |
SY-R1487 |
449808-64-4 |
详细
|
| B-Raf inhibitor 1 dihydrochloride |
B-Raf 抑制剂 1 二盐酸盐 |
1191385-19-9 |
详细
|
| cGAMP |
C-GPAP |
849214-04-6 |
详细
|
| Sparsentan (RE-021) |
4'-[(2-丁基-4-氧代-1,3-二氮杂螺[4.4]壬-1-烯-3-基)甲基]-N-(4,5-二甲基-3-异恶唑基)-2'-(乙氧基甲基)-[1,1'-联苯]-2-磺酰胺 |
254740-64-2 |
详细
|
| GPR39-C3 |
CS-2374 |
1621175-65-2 |
详细
|
| Avapritinib (BLU-285) |
阿伐普替尼 |
1703793-34-3 |
详细
|
| ZL0420 |
化合物ZL0420 |
2229039-45-4 |
详细
|
| HS1371 |
HS1371 |
2158197-70-5 |
详细
|
| PLX5622 |
PLX5622 |
1303420-67-8 |
详细
|
| Ponesimod |
PONESIMOD |
854107-55-4 |
详细
|
| CP 640186 |
(R)-ANTHRACEN-9-YL(3-(MORPHOLINE-4-CARBONYL)-1,4'-BIPIPERIDIN-1'-YL)METHANONE.HCL |
591778-68-6 |
详细
|
| AR7 |
CS-2649 |
80306-38-3 |
详细
|
| SP2509 |
无中文名称 |
1423715-09-6 |
详细
|
| Retro-2 |
2,3-DIHYDRO-2-(5-METHYL-2-THIENYL)-3-PHENYL-4(1H)-QUINAZOLINONE |
1429192-00-6 |
详细
|
| SAR-20347 |
CPDD1211 |
1450881-55-6 |
详细
|
| XY1 |
N-2-萘基-N'-[2-氧代-2-(1-吡咯烷基)乙基]脲 |
1624117-53-8 |
详细
|
| M2I-1 |
312271-03-7 |
312271-03-7 |
详细
|
| Nelonicline |
Nelonicline |
1026134-63-3 |
详细
|
| ARN-3236 |
3-(2,4-二甲氧基苯基)-4-(3-噻吩基)-1H-吡咯并[2,3-B]吡啶 |
1613710-01-2 |
详细
|
| C188-9 |
432001-19-9 |
432001-19-9 |
详细
|
| DC661 |
DC661 |
1872387-43-3 |
详细
|
| SRT2104 (GSK2245840) |
玻玛西林 |
1093403-33-8 |
详细
|
| SGC0946 |
SGC0946 |
1561178-17-3 |
详细
|
| HG-9-91-01 |
N-(2,4-二甲氧基苯基)-N'-(2,6-二甲基苯基)-N-[6-[[4-(4-甲基-1-哌嗪基)苯基]氨基]-4-嘧啶基]脲 |
1456858-58-4 |
详细
|
| N6-cyclohexyl-N2-(2-methyl-4-morpholinophenyl)-9H-purine-2,6-diamine |
N6-环己基-N2-(2-甲基-4-吗啉苯基)-9H-嘌呤-2,6-二胺 |
1246529-32-7 |
详细
|
| N/A |
4,4'-(pentane-1,5-diylbis(oxy))dibenzimidamide dihydrochloride |
50357-35-4 |
详细
|
| MK-8353 (SCH900353) |
化合物 T12069 |
1184173-73-6 |
详细
|
| MB-07811 ( VK-2809) |
MB-07811 |
852948-13-1 |
详细
|
| 2-(Hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-6,7-dimethoxy-N-[1-(phenylmethyl)-4-piperidinyl]-4-quinazolinamine hydrate trihydrochloride |
BIX 01294 |
935693-62-2 |
详细
|
| Eniporide |
N-(二氨基亚甲基)-2-甲基-5-(甲基磺酰基)-4-(1H-吡咯-1-基)苯甲酰胺 |
176644-21-6 |
详细
|
| Ki2 0227 |
Ki20227 |
623142-96-1 |
详细
|
| BMS-3 |
BMS-3 |
1338247-30-5 |
详细
|
| 2-[8-Chloro-6-(4-chloro-phenyl)-1-Methyl-4H-3-oxa-2,5-diaza-benzo[e]azulen-4-yl] |
化合物BET BROMODOMAIN INHIBITOR |
1505453-59-7 |
详细
|
| N-(4-ethylphenyl)-3-(hydroxymethyl)-N-isobutyl-4-((tetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide |
GSK2981278 |
1474110-21-8 |
详细
|
| JH-II-127 |
JH-II-127 |
1700693-08-8 |
详细
|
| Rogaratinib |
罗加替尼 |
1443530-05-9 |
详细
|
| BLU-782 |
BLU-782 |
2141955-96-4 |
详细
|
| Bohemine |
BOHEMINE |
189232-42-6 |
详细
|
| Capromorelin |
卡普瑞林 |
193273-66-4 |
详细
|
| SNX-5422 |
SNX-5422 |
908115-27-5 |
详细
|
| PCI 34051 |
N-羟基-1-(4-甲氧基苄基)-1H-吲哚-6-甲酰胺 |
950762-95-5 |
详细
|
| APY29 |
APY29 |
1216665-49-4 |
详细
|
| ML204 |
4-METHYL-2-(1-PIPERIDINYL)-QUINOLINE |
5465-86-1 |
详细
|
| 3-(4-morpholino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)benzonitrile |
PF-06447475 |
1527473-33-1 |
详细
|
| 5-(1-Methyl-1H-pyrazol-4-yl)-4-(4-morpholinyl)-7H-Pyrrolo[2,3-d]pyrimidine |
CS-2879 |
1527473-30-8 |
详细
|
| GSK2982772 |
GSK2982772 |
1622848-92-3 |
详细
|
| TA-01 |
TA 01 |
1784751-18-3 |
详细
|
| ML792 |
ML792 |
1644342-14-2 |
详细
|
| GSK |
GSK369796 |
1010411-21-8 |
详细
|
| ALK inhibitor 2 |
2-[[5-氯-2-[[2-甲氧基-4-(4-甲基-1-哌嗪基)苯基]氨基]-4-嘧啶基]氨基]-N-甲基苯磺酰胺 |
761438-38-4 |
详细
|
| URMC-099 |
URMC-099 |
1229582-33-5 |
详细
|
| Derazantinib (ARQ 087) |
德拉赞替尼 |
1234356-69-4 |
详细
|
| KO-947 |
KO-947 |
1695533-89-1 |
详细
|
| FM381 |
(E)-2-CYANO-3-(5-(1-CYCLOHEXYL-1,6-DIHYDROIMIDAZO[4,5-D]PYRROLO[2,3-B]PYRIDIN-2-YL)FURAN-2-YL)-N,N-DIMETHYLACRYLAMIDE |
2226521-65-7 |
详细
|
| BMS-5 |
BMS-5 |
1338247-35-0 |
详细
|
| HPI-4 |
HPI-4 |
302803-72-1 |
详细
|
| GDC-0623 |
GDC-0623 |
1168091-68-6 |
详细
|
| MSX-122 |
MSX 122 |
897657-95-3 |
详细
|
| ETC-1002 |
贝派地酸 |
738606-46-7 |
详细
|
| PQR309 Bimiralisib |
PI3K/MTOR抑制剂 |
1225037-39-7 |
详细
|
| SGC707 |
N-6-异喹啉基-N'-[2-氧代-2-(1-吡咯烷基)乙基]脲 |
1687736-54-4 |
详细
|
| BAY1125976 |
CS-2913 |
1402608-02-9 |
详细
|
| E6005 |
E6005 |
947620-48-6 |
详细
|
| BAY-8002 |
2-(2-氯-5-(苯基磺酰基)苯甲酰氨基)苯甲酸 |
724440-27-1 |
详细
|
| Monastrol |
CS-2432 |
254753-54-3 |
详细
|
| SGI-1776 |
SGI-1776 |
1025065-69-3 |
详细
|
| 4SC-202 tosylate |
4SC-202(盐的形式) |
1186222-89-8 |
详细
|
| Rocilinostat (ACY-1215) |
ACY1215 |
1316214-52-4 |
详细
|
| NIBR189 |
NIBR189 |
1599432-08-2 |
详细
|
| Tomivosertib eFT508 |
6'-[(6-氨基-4-嘧啶基)氨基]-8'-甲基螺[环己烷-1,3'(2'H)-咪唑并[1,5-A]吡啶]-1',5'-二酮 |
1849590-01-7 |
详细
|
| SF-2523 |
SF-2523 |
1174428-47-7 |
详细
|
| SNS-062 |
SNS062 |
1270014-40-8 |
详细
|
| Autophinib |
6-CHLORO-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-(4-NITROPHENOXY)PYRIMIDIN-4-AMINE |
1644443-47-9 |
详细
|
| Takinib |
1111556-37-6 |
1111556-37-6 |
详细
|
| FK866 |
(E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-pyridin-3-ylprop-2-enamide |
1198425-96-5 |
详细
|
| V-9302 |
V-9302 |
1855871-76-9 |
详细
|
| Emedastine |
依美斯汀 |
87233-61-2 |
详细
|
| PMPA(NAALADaseinhibitor) |
2-(PHOSPHONOMETHYL)PENTANEDIOIC ACID |
173039-10-6 |
详细
|
| PD-166285 |
6-(2,6-二氯苯基)-2-[[4-[2-(二乙基氨基)乙氧基]苯基]氨基]-8-甲基吡啶并[2,3-D]嘧啶-7(8H)-酮盐酸盐 |
212391-63-4 |
详细
|
| MSDC 0160 |
MSDC-0160 |
146062-49-9 |
详细
|
| U-104 |
U-104 |
178606-66-1 |
详细
|
| CNX2006 |
CNX2006 |
1375465-09-0 |
详细
|
| Entospletinib (GS-9973) |
GS-9973 |
1229208-44-9 |
详细
|
| Larotrectinib (LOXO-101 sulfate) |
(3S)-N-[5-[(2R)-2-(2,5-二氟苯基)-1-吡咯烷基]吡唑并[1,5-A]嘧啶-3-基]-3-羟基-1-吡咯烷甲酰胺硫酸盐 |
1223405-08-0 |
详细
|
| BBT594 |
BBT594 |
882405-89-2 |
详细
|
| AZD0364 |
CS-2696 |
2097416-76-5 |
详细
|
| LIT-927 |
LIT-927游离 |
2172879-52-4 |
详细
|